glp 1 if not overweight The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 This is why you’re not
Description
New data on Hengrui Pharma and Kailera Therapeutics investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S
The channeling of GLP-1 medicines via telehealth has come under criticism, most recently in the context of the Hims & Hers commercial that aired during the Superbowl LIX promoting the companys compounded therapy
Natural Ingredient Synergy

The most

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.
Why GLP-1 Support Matters
